# BioCity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biocity

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Website: www.biocitypharma.com
- Latest round: Series A (Jul 31, 2024)
- Investors on record: 3

## About

Based in Wuxi, China and founded in 2017, BioCity Biopharmaceutics Co., Ltd., trading as BioCity, operates as an innovative pharmaceutical company dedicated to providing innovative drugs for cancer treatment. It has an R&D Center in Shanghai. The founder and chair of the company, Xiangbo Jia, graduated from the Australian National University and has experience in entrepreneurship and investment in the biomedical field. The CEO of the company, Yongjiang Hei, graduated from Columbia University. In January 2026, BioCity closed venture funding from new investors Wuxi Zhidao Biotechnology Partnership (Limited Partnership), Wuxi Zhixin Biotechnology Partnership (Limited Partnership), Vivo Capital, with participation from other individual investor.

The company mainly provides BIC/FIC (Best in class/ First in Class) innovative drugs. The product pipeline targets kidney disease and tumors, and is indicated for IgA (Immunoglobulin A) nephropathy, diabetic nephropathy, solid tumors, small cell lung cancer, advanced ovarian cancer, and advanced hepatocellular carcinoma. BioCity also provides a translational medicine platform, which has the functions of predictive biomarker discovery and validation, new target validation, and drug resistance mechanism discovery.
The company generates revenue by providing innovative drugs for the treatment of tumors, chronic kidney disease and other diseases, as well as the translational medicine platform.

## Funding rounds

- Series A, Jul 31, 2024 — Wuxi Huading Venture Capital, WuXi Biologics (Cayman) Inc., Wuxi Yuanyue Private Equity Fund Management

## Investors

- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series A
- WuXi Biologics (Cayman) Inc. — Series A
- Wuxi Yuanyue Private Equity Fund Management (https://capitalatlas.ai/funds/wuxi-yuanyue-private-equity-fund-management) — Series A